Plain-English translation of NCT05572801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anal Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a circulating tumor DNA blood test — a test that looks for tiny traces of cancer in your bloodstream — can catch anal cancer recurrence earlier than standard imaging alone. Researchers want to see if this blood test, combined with regular follow-up care, helps doctors find cancer recurrence sooner, when surgery may still be able to cure it.
Anal cancer is rare but increasing in frequency. After initial treatment with chemotherapy and radiation, some patients experience treatment failure or cancer recurrence. Catching recurrence very early gives patients the best chance of successful surgery and cure — this blood test aims to provide that early warning.
You likely qualify if…
You likely don't qualify if…
You will receive the standard follow-up care for anal cancer, which includes regular imaging and clinical visits. Depending on which group you are placed in, you may also have additional imaging scans guided by blood test results. Throughout the study, you will donate blood samples at regular intervals so researchers can test for circulating tumor DNA and track whether the blood test helps catch recurrence earlier.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark
Finland